NCT01777776 - Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Locally Advanced Metastatic BRAF Mutant Melanoma

Interventions

DRUG

LEE011

LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).

DRUG

LGX818

LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).

Trial Locations (9)

Novartis Investigative Site, Westmead

Novartis Investigative Site, Woodville

Vanderbilt University Medical Center SC - Dept of Oncology ., Nashville

Karmanos Cancer Institute Dept of Oncology, Detroit

University of Colorado Dept of Oncology, Aurora

Memorial Sloan Kettering Cancer Center Dept Oncology, New York

Oregon Health & Science University Dept. of OHSU (3), Portland

Novartis Investigative Site, Montreal

Novartis Investigative Site, Utrecht